Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Rheumatoid arthritis (RA): a revolution in outcomes
- RA pathology
- Synovium - macroscopic
- Cells in joints: healthy and inflamed
- RA management (1990 - 2020)
- Radiological damage - determinant of disability
- Survival according to first year HAQ*
- RA: increased morbidity and mortality
- Summary: joint damage in RA
- Leiden early arthritis clinic
- TICORA* at 18 months
- Early RA in 2020
- TNF inhibitors
- TNF blockade
- Anti-TNF in established RA (I)
- ASPIRE study: structural damage
- TNF blockade in RA
- Originator anti-TNF biologics
- Anti-TNF and serious infections (SIs)
- TNF blockade and tuberculosis
- Intracellular infections
- Anti-TNF and malignancy meta-analysis
- Anti-TNF in established RA (II)
- Non-TNF inhibitors
- B cells in RA pathophysiology
- Protein CD20
- Rituximab - a chimeric murine antibody
- Serious infusions related reactions (IRRs)
- Infection rate
- Targeting T-cells: co-stimulation blockade
- CTLA4-Ig - immunoglobulin fusion protein
- IL-6 receptor blockade
- Systemic effects of IL-6
- Tocilizumab inhibits IL-6R signalling
- Tocilizumab: SAEs in clinical trials
- Summary: biological therapies for RA
- Biologic responsiveness in RA: precision medicine
- Biosimilars
- What is in a vial of therapeutic antibody?
- Biosimilars - the challenge
- Drug development pathways
- Regulatory requirements
- Advantages of biosimilars
- Disadvantages of biosimilars
- Immunogenicity
- Anti-drug antibodies (ADAs)
- Conclusions
Topics Covered
- Pathology of rheumatoid arthritis
- Management of rheumatoid arthritis
- Biological therapies for rheumatoid arthritis
- TNF inhibitors, non-TNF inhibitors, and biosimilars
- Clinical trials for rheumatoid arthritis
Links
Series:
- The Immune System - Key Concepts and Questions
- Monoclonal Antibodies as Therapeutic Agents
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Isaacs, J. (2020, May 31). Modern management of rheumatoid arthritis - with a focus on biologic therapies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 6, 2024, from https://doi.org/10.69645/URXB7003.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is John Isaacs,
I'm Professor of Clinical Rheumatology
at Newcastle University, and
my presentation is on modern therapy for
rheumatoid arthritis.
0:13
There's been a revolution in rheumatoid
arthritis outcomes over the last 30 years,
in the image on the left is a typical
rheumatoid arthritis patient from
the 1990s when I started seeing rheumatoid
arthritis patients, and on the right is
how I would expect my patients to look
today, you can see the big difference.
0:32
To understand what's going on,
I wanted to talk a little bit about
rheumatoid arthritis pathology.
In this cartoon, the left hand side shows
a normal joint, and the right hand side
shows the equivalent joint in
a person with rheumatoid arthritis.
You can see there are two bones there and
they're joined by the brown joint capsule,
the yellow is the articular cartilage
(the gristle), and the really important
thing we're going to talk about is
the synovium, or the pink line.
In health you can see this
membrane is quite thin,
in rheumatoid it becomes a very bulky
proliferating tissue, and you can
see that proliferating tissue is actually
invading into the cartilage and bone.
In fact when we do imaging such as X-rays,
MRI-scans or CT-scans, we look for
erosions which are holes in the bone,
as you can see indicated by the arrow,
this is effectively an image
of that invading synovium.
1:30
The next slide shows what you would
see if you looked into a joint.
On the left hand side (using an
arthroscope), in a normal joint you can't
see the synovial membrane, it's so
thin that it's transparent and
you're looking at the blood vessels
underlying the synovial membrane.
On the right,
you can see an inflamed joint, and
what you can see in this joint is that
because of the proliferating bulky
synovium it's now forming polyploid
processes protruding into the joint.
Below that you can see
a more chronic picture,
there's lots of fibrin and
a very messy interior to that joint.
Hide